 Livia Veress
Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mustard Gas | 16 | 2024 | 117 | 4.740 |
Why?
| | Chemical Warfare Agents | 15 | 2024 | 121 | 3.740 |
Why?
| | Airway Obstruction | 8 | 2021 | 170 | 2.130 |
Why?
| | Inhalation Exposure | 13 | 2018 | 103 | 2.060 |
Why?
| | Bronchiolitis Obliterans | 3 | 2018 | 66 | 1.790 |
Why?
| | Fibrinolytic Agents | 5 | 2020 | 233 | 1.480 |
Why?
| | Respiratory Insufficiency | 5 | 2023 | 292 | 1.430 |
Why?
| | Fontan Procedure | 2 | 2021 | 157 | 1.210 |
Why?
| | Tissue Plasminogen Activator | 4 | 2020 | 228 | 1.090 |
Why?
| | Bronchitis | 3 | 2021 | 37 | 1.040 |
Why?
| | Pulmonary Fibrosis | 2 | 2018 | 331 | 1.000 |
Why?
| | Lung | 8 | 2024 | 3685 | 0.940 |
Why?
| | Respiratory Mucosa | 2 | 2017 | 261 | 0.890 |
Why?
| | Rats, Sprague-Dawley | 17 | 2020 | 2262 | 0.860 |
Why?
| | Epithelial Cells | 3 | 2020 | 965 | 0.850 |
Why?
| | Chlorine | 3 | 2018 | 62 | 0.830 |
Why?
| | Cytotoxins | 1 | 2020 | 17 | 0.720 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2021 | 139 | 0.710 |
Why?
| | Isocyanates | 5 | 2022 | 15 | 0.710 |
Why?
| | Mechlorethamine | 1 | 2020 | 64 | 0.690 |
Why?
| | Toxicity Tests | 2 | 2018 | 27 | 0.630 |
Why?
| | Rats | 15 | 2024 | 5035 | 0.630 |
Why?
| | Blood Coagulation | 2 | 2018 | 221 | 0.620 |
Why?
| | Thrombolytic Therapy | 2 | 2020 | 118 | 0.620 |
Why?
| | Arterioles | 1 | 2017 | 40 | 0.600 |
Why?
| | Cardiac Output | 1 | 2018 | 143 | 0.590 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 504 | 0.590 |
Why?
| | Oxygen | 4 | 2018 | 839 | 0.580 |
Why?
| | Postoperative Care | 1 | 2018 | 222 | 0.550 |
Why?
| | Acute Lung Injury | 2 | 2016 | 302 | 0.520 |
Why?
| | Endothelial Cells | 1 | 2020 | 694 | 0.490 |
Why?
| | Lung Diseases | 2 | 2018 | 710 | 0.480 |
Why?
| | Thrombosis | 1 | 2017 | 302 | 0.470 |
Why?
| | Fibrin | 5 | 2023 | 65 | 0.460 |
Why?
| | Bronchi | 3 | 2023 | 253 | 0.460 |
Why?
| | Animals | 25 | 2024 | 32123 | 0.420 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 346 | 0.400 |
Why?
| | Myocytes, Cardiac | 2 | 2015 | 456 | 0.370 |
Why?
| | Administration, Inhalation | 4 | 2018 | 647 | 0.370 |
Why?
| | Cell Differentiation | 1 | 2017 | 1707 | 0.350 |
Why?
| | Cell Proliferation | 1 | 2017 | 2196 | 0.350 |
Why?
| | Bronchoalveolar Lavage Fluid | 7 | 2018 | 609 | 0.310 |
Why?
| | Postoperative Complications | 1 | 2018 | 2167 | 0.290 |
Why?
| | Fibrinolysis | 3 | 2020 | 160 | 0.290 |
Why?
| | Respiratory Function Tests | 2 | 2018 | 541 | 0.270 |
Why?
| | Thromboplastin | 2 | 2018 | 71 | 0.250 |
Why?
| | Lung Injury | 2 | 2017 | 201 | 0.240 |
Why?
| | Male | 18 | 2020 | 56128 | 0.220 |
Why?
| | Metalloporphyrins | 2 | 2016 | 106 | 0.220 |
Why?
| | Pesticides | 1 | 2022 | 49 | 0.200 |
Why?
| | Disease Models, Animal | 5 | 2020 | 3582 | 0.200 |
Why?
| | Antioxidants | 3 | 2016 | 533 | 0.200 |
Why?
| | Gas Chromatography-Mass Spectrometry | 2 | 2018 | 128 | 0.190 |
Why?
| | Plasminogen Activator Inhibitor 1 | 2 | 2018 | 82 | 0.180 |
Why?
| | Hemoglobins | 1 | 2022 | 313 | 0.180 |
Why?
| | Antidotes | 2 | 2024 | 135 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2018 | 1868 | 0.170 |
Why?
| | Trachea | 2 | 2018 | 234 | 0.160 |
Why?
| | Sulfur Compounds | 1 | 2018 | 5 | 0.160 |
Why?
| | Hydantoins | 1 | 2018 | 5 | 0.160 |
Why?
| | Oxides | 1 | 2018 | 43 | 0.160 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2018 | 81 | 0.150 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2018 | 41 | 0.150 |
Why?
| | Medical History Taking | 1 | 2018 | 115 | 0.150 |
Why?
| | Hypercapnia | 1 | 2018 | 50 | 0.150 |
Why?
| | Blood Coagulation Disorders | 1 | 2020 | 196 | 0.150 |
Why?
| | Accidents, Occupational | 1 | 2017 | 15 | 0.150 |
Why?
| | Tomography, Optical Coherence | 1 | 2018 | 128 | 0.150 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2018 | 155 | 0.150 |
Why?
| | Platelet Aggregation | 1 | 2017 | 94 | 0.140 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2017 | 82 | 0.140 |
Why?
| | Airway Remodeling | 1 | 2017 | 60 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 253 | 0.140 |
Why?
| | Physical Examination | 1 | 2018 | 224 | 0.140 |
Why?
| | Receptors, Notch | 1 | 2017 | 85 | 0.140 |
Why?
| | Computed Tomography Angiography | 1 | 2017 | 107 | 0.140 |
Why?
| | Disaster Planning | 1 | 2017 | 77 | 0.140 |
Why?
| | Disasters | 1 | 2017 | 89 | 0.130 |
Why?
| | Endoscopy | 1 | 2018 | 247 | 0.130 |
Why?
| | Exercise Test | 1 | 2018 | 541 | 0.130 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2015 | 36 | 0.130 |
Why?
| | Acute Disease | 1 | 2018 | 917 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 343 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 335 | 0.120 |
Why?
| | Imaging, Three-Dimensional | 1 | 2018 | 496 | 0.120 |
Why?
| | Microdissection | 2 | 2013 | 15 | 0.120 |
Why?
| | Cell Line | 1 | 2020 | 2655 | 0.120 |
Why?
| | Pulmonary Ventilation | 1 | 2014 | 68 | 0.120 |
Why?
| | Capillary Permeability | 2 | 2014 | 138 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2020 | 1033 | 0.120 |
Why?
| | Antifibrinolytic Agents | 1 | 2014 | 50 | 0.110 |
Why?
| | Electric Impedance | 1 | 2014 | 99 | 0.110 |
Why?
| | Respiration | 1 | 2014 | 180 | 0.110 |
Why?
| | Weight Loss | 1 | 2018 | 632 | 0.110 |
Why?
| | Acidosis | 1 | 2014 | 87 | 0.110 |
Why?
| | Environmental Exposure | 1 | 2017 | 381 | 0.110 |
Why?
| | Humans | 10 | 2023 | 115908 | 0.110 |
Why?
| | Immunoglobulin M | 2 | 2013 | 251 | 0.110 |
Why?
| | Heparin | 1 | 2014 | 226 | 0.110 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 724 | 0.100 |
Why?
| | Child | 3 | 2021 | 18555 | 0.100 |
Why?
| | Oxidative Stress | 2 | 2016 | 1096 | 0.100 |
Why?
| | Lipoproteins | 1 | 2013 | 162 | 0.100 |
Why?
| | Time Factors | 4 | 2016 | 6186 | 0.100 |
Why?
| | Incidence | 1 | 2018 | 2333 | 0.100 |
Why?
| | Heart Diseases | 1 | 2015 | 337 | 0.100 |
Why?
| | Blotting, Western | 2 | 2013 | 1153 | 0.100 |
Why?
| | Pneumonia | 1 | 2016 | 576 | 0.090 |
Why?
| | Algorithms | 1 | 2018 | 1494 | 0.090 |
Why?
| | Gene Expression Regulation | 1 | 2020 | 2362 | 0.090 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 298 | 0.080 |
Why?
| | Limit of Detection | 2 | 2018 | 56 | 0.080 |
Why?
| | Child, Preschool | 2 | 2018 | 9175 | 0.070 |
Why?
| | Mesna | 1 | 2024 | 17 | 0.060 |
Why?
| | Models, Animal | 2 | 2017 | 350 | 0.060 |
Why?
| | Sodium | 1 | 2024 | 182 | 0.050 |
Why?
| | Young Adult | 1 | 2018 | 10518 | 0.050 |
Why?
| | Pronase | 1 | 2022 | 5 | 0.050 |
Why?
| | Carbamates | 1 | 2022 | 35 | 0.050 |
Why?
| | Phenols | 1 | 2022 | 84 | 0.050 |
Why?
| | Tyrosine | 1 | 2022 | 218 | 0.050 |
Why?
| | Retrospective Studies | 1 | 2018 | 12616 | 0.050 |
Why?
| | Erythrocytes | 2 | 2018 | 590 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2018 | 2814 | 0.050 |
Why?
| | Biomarkers | 2 | 2022 | 3474 | 0.040 |
Why?
| | Adolescent | 1 | 2018 | 17955 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2020 | 286 | 0.040 |
Why?
| | Liquid-Liquid Extraction | 1 | 2018 | 15 | 0.040 |
Why?
| | Female | 3 | 2020 | 60086 | 0.040 |
Why?
| | Thoracic Duct | 1 | 2017 | 3 | 0.040 |
Why?
| | Mice | 1 | 2014 | 15075 | 0.040 |
Why?
| | Chemical Terrorism | 1 | 2017 | 5 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 296 | 0.040 |
Why?
| | Proteins | 2 | 2013 | 922 | 0.030 |
Why?
| | Recovery of Function | 1 | 2020 | 578 | 0.030 |
Why?
| | Swine | 1 | 2018 | 706 | 0.030 |
Why?
| | Embolization, Therapeutic | 1 | 2017 | 181 | 0.030 |
Why?
| | Etiocholanolone | 1 | 2015 | 7 | 0.030 |
Why?
| | Ranolazine | 1 | 2015 | 22 | 0.030 |
Why?
| | Thiocyanates | 1 | 2015 | 29 | 0.030 |
Why?
| | alpha-2-Antiplasmin | 1 | 2014 | 3 | 0.030 |
Why?
| | Carboxypeptidase B2 | 1 | 2014 | 4 | 0.030 |
Why?
| | Mitochondria, Heart | 1 | 2015 | 73 | 0.030 |
Why?
| | Blood-Air Barrier | 1 | 2014 | 10 | 0.030 |
Why?
| | Cardiotonic Agents | 1 | 2015 | 119 | 0.030 |
Why?
| | Drug Administration Routes | 1 | 2014 | 41 | 0.030 |
Why?
| | Blood Coagulation Tests | 1 | 2014 | 57 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2016 | 552 | 0.030 |
Why?
| | Altitude | 1 | 2017 | 410 | 0.030 |
Why?
| | Prothrombin | 1 | 2013 | 22 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2016 | 481 | 0.030 |
Why?
| | Societies, Medical | 1 | 2017 | 690 | 0.030 |
Why?
| | Indicators and Reagents | 1 | 2013 | 100 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2015 | 212 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 2015 | 430 | 0.030 |
Why?
| | Hypoxia | 1 | 2018 | 937 | 0.030 |
Why?
| | Pandemics | 1 | 2020 | 1333 | 0.020 |
Why?
| | Factor VII | 1 | 2011 | 26 | 0.020 |
Why?
| | Factor Xa | 1 | 2011 | 32 | 0.020 |
Why?
| | Milk Proteins | 1 | 2011 | 36 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2011 | 133 | 0.020 |
Why?
| | Antigens, Surface | 1 | 2011 | 151 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 794 | 0.020 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2010 | 107 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1243 | 0.020 |
Why?
| | Myocardium | 1 | 2015 | 929 | 0.020 |
Why?
| | Peroxidase | 1 | 2010 | 157 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1643 | 0.020 |
Why?
| | Cytokines | 1 | 2016 | 1857 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2015 | 3916 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2020 | 9166 | 0.020 |
Why?
| | Apoptosis | 1 | 2015 | 2377 | 0.020 |
Why?
| | Aged | 1 | 2020 | 19299 | 0.010 |
Why?
| | United States | 1 | 2017 | 12338 | 0.010 |
Why?
| | Middle Aged | 1 | 2020 | 27084 | 0.010 |
Why?
| | Inflammation | 1 | 2010 | 2503 | 0.010 |
Why?
|
|
Veress's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|